- Home
- PNF vs ONCY Comparison
PNF vs ONCY Comparison
Compare PNF & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNF
- ONCY
- Stock Information
- Founded
- PNF 2001
- ONCY 1998
- Country
- PNF United States
- ONCY Canada
- Employees
- PNF N/A
- ONCY N/A
- Industry
- PNF Finance Companies
- ONCY Pharmaceuticals and Biotechnology
- Sector
- PNF Finance
- ONCY Health Care
- Exchange
- PNF Nasdaq
- ONCY Nasdaq
- Market Cap
- PNF 54.9M
- ONCY 49.1M
- IPO Year
- PNF N/A
- ONCY 1999
- Fundamental
- Price
- PNF $6.95
- ONCY $0.34
- Analyst Decision
- PNF
- ONCY Strong Buy
- Analyst Count
- PNF 0
- ONCY 4
- Target Price
- PNF N/A
- ONCY $4.33
- AVG Volume (30 Days)
- PNF 29.1K
- ONCY 889.1K
- Earning Date
- PNF 01-01-0001
- ONCY 07-31-2025
- Dividend Yield
- PNF 5.17%
- ONCY N/A
- EPS Growth
- PNF N/A
- ONCY N/A
- EPS
- PNF N/A
- ONCY N/A
- Revenue
- PNF N/A
- ONCY N/A
- Revenue This Year
- PNF N/A
- ONCY N/A
- Revenue Next Year
- PNF N/A
- ONCY N/A
- P/E Ratio
- PNF N/A
- ONCY N/A
- Revenue Growth
- PNF N/A
- ONCY N/A
- 52 Week Low
- PNF $6.37
- ONCY $0.33
- 52 Week High
- PNF $9.06
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- PNF 44.80
- ONCY 25.45
- Support Level
- PNF $6.90
- ONCY $0.37
- Resistance Level
- PNF $6.97
- ONCY $0.37
- Average True Range (ATR)
- PNF 0.07
- ONCY 0.04
- MACD
- PNF 0.00
- ONCY -0.01
- Stochastic Oscillator
- PNF 40.00
- ONCY 4.95
About PNF PIMCO New York Municipal Income Fund
PIMCO New York Municipal Income Fund is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund's portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.